Evidence map›Paper›PMID 28444446›Full record

ArticleJournal of neurology2017

Comparison of the clinical and cognitive features of genetically positive ALS patients from the largest tertiary center in Serbia.

Ivan V Marjanović, Biljana Selak-Djokić, Stojan Perić, Milena Janković, Vladimir Arsenijević, Ivana Basta, Dragana Lavrnić, Elka Stefanova, Zorica Stević

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. ALS-plus related clinical and genetic study from China.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ivan V MarjanovićNeurology Clinic, Clinical Center of Serbia, School of Medicine, University in Belgrade, Dr Subotica 6, 11000, Belgrade, Serbia. ivan020979@gmail.com.
Biljana Selak-DjokićNeurology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
Stojan PerićNeurology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
Milena JankovićNeurology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
Vladimir ArsenijevićEmergency Department, Clinic for Emergency Surgery, Clinical Center of Serbia, Belgrade, Serbia.
Ivana BastaNeurology Clinic, Clinical Center of Serbia, School of Medicine, University in Belgrade, Dr Subotica 6, 11000, Belgrade, Serbia.
Dragana LavrnićNeurology Clinic, Clinical Center of Serbia, School of Medicine, University in Belgrade, Dr Subotica 6, 11000, Belgrade, Serbia.
Elka StefanovaNeurology Clinic, Clinical Center of Serbia, School of Medicine, University in Belgrade, Dr Subotica 6, 11000, Belgrade, Serbia.
Zorica StevićNeurology Clinic, Clinical Center of Serbia, School of Medicine, University in Belgrade, Dr Subotica 6, 11000, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Discovering novel mutations in C9orf72, FUS, ANG, and TDP-43 genes in ALS patients arises necessities for better clinical characterizations of these subjects. The aim is to determine clinical and cognitive profile of genetically positive Serbian ALS patients. 241 ALS patients were included in the study (17 familiar and 224 apparently sporadic). The following genes were analyzed: SOD1, C9orf72, ANG, FUS, and TDP-43. An extensive battery of classic neuropsychological tests was used in 27 ALS patients (22 SOD1 positive and 5 SOD1 negative) and 82 healthy controls (HCs). Overall 37 (15.4%) of 241 ALS patients carried mutations in tested genes-among 17 familiar ALS patients 16 (94.1%) were positive and among 224 apparently sporadic 21 (9.4%) had causative mutation. Mutations in SOD1 gene were the most common, representing 27 (73.0%) of all genetically positive ALS patients. The main clinical characteristics of SOD1 positive patients were: spinal onset in lower extremities, common sphincter and sensitive disturbances, and dysexecutive syndrome. Within SOD1 positive patients, we noticed somewhat earlier onset in patients with A145G, sensory and sphincter disturbances were dominant in patients with L144F, while D90A patients had significant sensory involvement. SOD1 negative group consisted of ten (27.0%) patients (six C9orf72, two ANG, one TDP-43, and one patient baring triple FUS, C9orf72 expansion, and ANG variants). Bulbar involvement and more extensive neuropsychological impairment (including executive, visuospatial, and memory difficulties) were the main features of SOD1 negative cohort. Our results suggest that meaningful clinical suspicion of certain ALS genotype might be made based on thorough clinical evaluation of patients.

Indexed as

Amyotrophic Lateral SclerosisC9orf72 ProteinCognition DisordersCohort StudiesDisability EvaluationDNA-Binding ProteinsFemaleGenetic Association StudiesGenetic TestingHumansMaleMutationNeuropsychological TestsRibonuclease, PancreaticRNA-Binding Protein FUSSerbiaangiogeninC9orf72 ProteinDNA-Binding ProteinsFUS protein, humanRibonuclease, PancreaticRNA-Binding Protein FUSSOD1 protein, humanSuperoxide Dismutase-1TARDBP protein, humanALSC9orf72CognitionGeneticsSOD1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.